Paraguayan health authorities reported Monday that only 64% of the 1,500,000 influenza vaccine doses available nationwide had ...

Merck’s Enflonsia (clesrovimab) has received US Food and Drug Administration (FDA) approval for the prevention of respiratory ...

The approval was based on data from the pivotal Phase IIb/III CLEVER trial which assessed a single dose of the antibody.

The FDA has approved Enflonsia (clesrovimab-cfor) for the prevention of RSV lower respiratory tract disease in neonates and ...

The United States could soon have another tool in the fight against respiratory syncytial virus, an illness that’s the No. 1 ...

MRK wins early FDA approval for RSV antibody Enflonsia in infants, with U.S. launch planned before the 2025-26 season.

The Friday release says Alberta will provide COVID vaccines free of charge to residents of supportive living facilities, ...

EDMONTON – Alberta Premier Danielle Smith says her government’s new policy forcing many Albertans to pay out of pocket for a ...

Approval of Enflonsia was based on data from the Phase IIb/III CLEVER trial, which showed a 60.5% reduction in medically ...

A newly approved shot could soon help protect babies from respiratory syncytial virus (RSV), the top cause of hospitalization ...

The green light in the US is the first worldwide for Enflonsia ( clesrovimab) and makes the long-acting antibody the first ...

Africa's Department of Agriculture is urged to negotiate a new trade agreement with Brazil to ensure the continuous import of ...